12345...102030...


UTRGV to offer 10th school of podiatric medicine in entire nation – KGBT-TV

EDINBURG, Texas (KVEO) UTRGVSSchool of Medicineis growing againbyaddingapodiatry program the only one inTexas.

Historically, anyone inTexaswho wanted to be a podiatrist had to leave the state to get a degree to come back,Dr. Lawrence Harkless,UTRGV School of Podiatry interim dean said.

Dr.Harkless came out of retirementto serve as the new schools deanand prepare the academic plan.

We will be taking the classes the medical school takes in the first two years,and then we will start teaching more podiatry-specific courses earlier,he said.

Dr. Harkless previously helped establish aCollege ofPodiatricMedicine inPomona,California, and saysstudent mentorship will be at the forefront of this new program.

The foundation for that would be learn, serve, lead,he said.

According to theAmericanDiabetesAssociation, theRGV has a diabetes rate three times higher than the national average, whichDr.Harkless says makes the area an ideal spot fortheschool.

(People) Can really stay inthecommunity where they grewup andserve,he said.

The inaugural class will be welcomed in the fall of 2022,andUTRGVisalready looking to hire 20 faculty with a passion for both teaching as well as research.

Tohaveexcellence in a student, every faculty member has to be excellentbecause they have to be able to teach thatwhetherin basic science, two years theory andfactorwhetherin clinical years, he said.

Along with theSouthTexasDiabetes andObesityInstitute ofBrownsville,Dr.Harkless says theRGV could become medical leaders over genetics and genomics of the feet.

Read the original here:

UTRGV to offer 10th school of podiatric medicine in entire nation - KGBT-TV

Burnout: The Experience of Women In Medicine During COVID-19 – The Doctor Weighs In

Women in medicine are at risk of physician burnout due to COVID-19 due to many different factors, including:

Further, they must continue to deal with all of the job-related stress that existed before the pandemic, including:

No wonder women in medicine are feeling overwhelmed and are at risk of burnout.

Since the onset of COVID-19, people worldwide have had to learn to adapt to change quickly. The problem with this, however, is that our brain doesnt like change. It likes to predict the future and when we face change, this means one thing: uncertainty.

The pandemic has turned the world as we knew it upside-down. Things we previously took for granted, like getting together with friends or going to work, became risky.

In addition to dealing with the possibility of contracting COVID through everyday activities, medical professionals are also at increased risk of contracting the virus through the treatment of their sick patients.

Related Content:Survey Shows Women in Medicine Still Face InequitiesPrioritizing Healthcare Workers Mental Health During COVID-19

While they are needed now more than ever, medical professionals are losing their jobs and experiencing a reduction in pay and hours. Those who have not yet been affected are worried about the future of their career and financial stability.

Because most schools in the United States have switched over to a digital format, much of childcare and homeschooling have fallen on parents. Traditionally, women have been the primary ones to handle work within the home. [3] Therefore, it is not a far stretch to imagine that they are also the ones who are taking on most of these domestic tasks now.

While these women might be high achievers, many say they are working hard for their families. The trouble is their career takes up so much of their time that they have less time to spend with their loved ones. Even when they have the time, they often experience emotional exhaustion, [4] which may keep them from being fully present.

Perhaps, that is why 40 percent of female physicians end up leaving or cutting back their hours by their sixth year [5]. A similar trend can be seen with female nurses whose turnover rates are purported to be as high as 38 percent.[6] However, working less can bring up additional stress related to paying back student loans and other financial debt.

For all these reasons, being a woman in medicine now more than ever can feel like being in survival mode. Indeed, when demands are excessive and resources are short, this is a recipe for burnout [7].

As it turns out, 42 percent of physicians reported being burned out according to a recent online survey [8]. A similar trend can be seen with nurses who normally experience emotional pressures in their jobs which, during a pandemic, can lead to stress and burnout. [9]

When these professionals are not at their best, they suffer a decrease in energy, morale, and job performance. And, the quality of their medical care goes down.

The effect of this trickles down to patients who receive poorer quality care. And they may suffer higher rates of infections and increased mortality rates due to medical errors. [10]

Some women in medicine may turn to junk food or overindulge in drugs or alcohol to cope with stress. Such maladaptive coping translates into weight gain, poorer health, and addictions. All of these things have further consequences that negatively affect sleep, mood, and relationships.

While the external stressors they face are real, it is up to the individual to learn to manage their thinking to avoid feeling anxious, overwhelmed or burned out. This is possible even during COVID-19.

In addition to environmental stressors, part of the reason why anxiety and burnout are an epidemic among healthcare workers is because of the stigma around mental health in the field of medicine.

There is an expectation that healthcare providers are superhuman. And, that they can manage to deal with emotionally draining and sometimes traumatic experiences while navigating challenging work-related conditions without being affected. This is clearly unrealistic and very damaging to their long-term well-being.

Nevertheless, not all hope is lost. The key to staying afloat amid the chaos is self-management. It may seem that the reasons for the stress are external factors and therefore beyond your control. However, our response to stress is a product of our minds.

Think of a time when you were in the same situation as someone else. While you may have been negatively affected by the circumstances at the time, your friend or colleague was unphased.

The reason for this difference in outcomes relates to perception. It is not what happens to us that makes us feel how we do. Rather, it is how we think about what happens to us that leads to those feelings.

When we misunderstand someones intention, we can feel upset by our interpretation. Once we realize what they truly meant, our perception shifts. Consequently, so do our feelings.

The same is true in the workplace. It is your thinking that creates your current emotional state, not the circumstances. When you shift your mindset, you shift your anxiety into a state of calm.

The next time you find yourself ruminating about mistakes youve made or worrying about the future, bring yourself back to the present moment. Recognize that you have a choice about where you focus your mind.

The world around you will remain imperfect. The healthcare system in which you work will continue to be deeply flawed.

When you fixate on what should be different, youll only feel frustrated. Instead, focus inward on what you can control. This is because the only thing you have control over is yourself.

By learning to manage your thinking, you can make positive changes, such as:

The responsibility of self-management and self-care may seem like an added burden to your already burdened life. However, by increasing Emotional Intelligence and managing your energy, you lighten your load.

What may have seemed overwhelming previously may feel easier when your perspective shifts, when you are in a state of balance, and when you are able to accept aspects that exist outside your control.

You are stronger than you realize and no matter what, rememberyou always have a choice.

During the COVID-19 pandemic, women in medicine have been faced with heightened demands and lower than normal resources. This combination can overwhelm and bring about anxiety and burnout.

By focusing internally rather than externally, you can regain control over your reactions and refocus on what really matters long-term.

Follow this link:

Burnout: The Experience of Women In Medicine During COVID-19 - The Doctor Weighs In

Meet the power couple who are changing the face of veterinary medicine – Jill Lopez

Dr. Valerie Marcano and Dr. Seth Andrews are more than just a couple in love, together they are working to make veterinary medicine more diverse - something that the veterinary profession desperately needs help with. In 2013, the profession of veterinary medicine was named the whitest profession by The Atlantic magazine. This report mirrored another report in the Journal of Blacks in Higher Education, which gave veterinary medicine the designation as most segregated of all the health professions.

Dr. Valerie completed her DVM and PhD at the University of Georgia ((2017 and 2020) and is a Poultry Technical Consultant at Elanco Animal Health as well as the chair of the Diversity and Inclusion Committee of the American Association of Avian Pathologists.

Dr. Seth Andrews, the other half of the team, is a Process Engineer with Precision BioSciences. He completed a post-doc at the University of Georgia after earning his PhD in Biological Engineering from the University of Georgia in 2019. He received his Bachelor of Science and Master of Engineering from Cornell University.

As fate would have it, he would meet Valerie at Cornell University. They were both a member of Cornells Alpha Zeta fraternity. Valerie made fun of Seth for eating his pizza with a knife and a fork, but it ended up working out as a beautiful relationship.

Together they created Pawsibilities Vet Med - a web and mobile platform designed to aid in the recruitment and retention of diverse students in the veterinary profession through resources, discussion forums and the showcasing of diverse veterinarians. Pawsibilities aims to connect individuals from underrepresented backgrounds interested in the veterinary profession to both opportunities available and to potential mentors and advisors within the field through a mentorship platform.

Pawsibilities Vet Med pools available resources and provides information about veterinary medicine to educate students about the myriad of paths they may take within the profession. It also provides a forum to discuss the various challenges and pitfalls on the path to becoming a veterinarian or veterinary technician. Pawsibilities Vet Med also showcases veterinarians and veterinary technicians from a variety of backgrounds, to emphasize that anyone from anywhere can join the profession.

Together, they hope to give people of color an easier path into veterinary medicine, while also enriching the lives of those who have already made it and providing them the care they need. Their work is the perfect example of how veterinarians should be and also what the future can look like if more people think and act like them.

We caught up Dr. Valerie to learn more:

How we met

We met while attendingCornell Universitys Alpha Zeta fraternity during the Fall of 2009. We were both Sophomores.Its a funny story but essentially I made fun of Seth for eating pizza with a fork and knife.

Who DTR (defined the relationship)

I did!

Secrets to working with your spouse

Our secret to working with each other is having lots of patience and utilizing each others strengths. Seth is really good with website design and technical issues, while I am very good at coming up with ideas.

Best part of working together: Being able to communicate when you have ideas and often being on the same page

Worst part of working together:

Talking about work all the time - sometimes we feel like we need to keep working and if we are doing something fun, we feel like we should be working instead. We often have to remind each other that it is ok to take a night off.

Who I admire most and why:

I have a number ofveterinary women that have truly been my rock and inspiration - trailblazers in the profession that have paved the path I walk on. I remember my first visit to the University of Georgia and meeting Dr. Paige Carmichael, at the time the Associate Dean for Academic Affairs, and Dr. Kaori Sakamoto, at the time the Program Coordinator for the UGA College of Veterinary Medicine's Veterinary Medical Scientist Training dual DVM-PhD degree program. I remember being in awe of these highly trained dual board certified DVM and PhD women of color and have been truly fortunate to have had them become mentors and friends.

Best advice I ever received:

Keep your options open. I was set on a specific job after graduation and one of my mentors, and the person who would have been my supervisor in that position told me to keep my options open. I did and have not regretted it one bit.

Why it is time for Pawsibilities Vet Med:

Because diversity promotes growth - within individuals and the profession as a whole. Diversity, paired with proper training in equity and inclusion, brings about wellness in our profession. Mentorship constitutes support - a clan, a village. It supports the concept that we stand on the shoulder of giants and gives us the chance to pave an even better path for those before us.

Looking to advance or start your career in veterinary medicine? Want to give back to the future of veterinary medicine? Both? Sign up here!

Pawsibility Vet Med

Go here to see the original:

Meet the power couple who are changing the face of veterinary medicine - Jill Lopez

Biracial Stanford physician: We must look beyond race in medicine – Scope

In an August column in STAT News, Megan Mahoney, MD, Stanford Health Care's chief of staff, wrote, "In medical school, I was diligently trained to report to my attending physicians the age, race, and gender of my patients -- in that order."

She wondered how a doctor would describe her, a biracial woman, and what the medical consequences might be for her.

For a 1:2:1 podcast, I spoke with Mahoney, a family medicine clinician, about her background; about race and how it plays out in clinical settings; and about what needs to change to overcome systemic racial inequities in the nation's health care system.

This Q&A is edited and condensed from that conversation.

You wrote in your column: "It's time to stop using skin color and race in medicine and see patients for who they really are." It came out of your experience as a biracial woman. Tell me about your parents.

My father was born to Irish-American parents. After graduating from prep school and the U.S. Naval Academy, he married, but he lost his wife to meningitis. He decided to go into the priesthood. As a priest, he began working in Memphis and became very active in the civil rights movement.

My mother was born in Memphis -- the Jim Crow South -- as one of 13 children. Sometimes all the family had to eat were peaches from the trees in their backyard.

She received a full scholarship to a small Catholic college in Kansas. She returned to Memphis after college to teach at a high school. She also was treasurer at the Catholic parish church where my father served, which is how they met.

My mother received a PhD in mathematics, and later was one of the first African-American women in the United States to become a university president. She served as president of Lincoln University of Missouri for seven years.

My father was by her side throughout her career. It was quite a love story.

When were you first aware of being biracial?

I grew up in Columbus, Ohio. I was in kindergarten, the very first day of school, on the playground with a group of kids. They looked at me quizzically, trying to size me up, and asked, "So, what are you?" I had no idea what they were referring to.

Later, at the dinner table, I asked my parents, "There's this question I'm not really sure how to answer." They told me to go back the next day. If I was asked again, I should respond, "I'm mixed." I felt very prepared. I went back and was asked again, "What are you?" I responded, "I'm mixed up."

As you moved through life, college and medical school, how did being a biracial woman impact you?

For most of my adult life, I was categorized as "other." On applications for various schools, I've had to be limited in how I describe my racial background. They'd ask, White, African American, Asian, Pacific Islander, Hispanic, but there often was not a box that gave me an opportunity to write in, "White and Black."

When I was in high school, my counselors were pushing me towards Ivy League colleges, but I selected a school -- UC Berkeley -- because of its racial diversity.

For the first time, I could experience being surrounded by people of all different backgrounds. I can just share with you that that sense of belonging was truly cherished. For once, I didn't have to be asked, "Where are you really from?" It didn't matter.

In your opinion piece for STAT news, you write that it's time for medicine to look beyond race as a determinant factor and see people as individuals.

The practice of medicine has not truly accounted for mixed-race individuals and lacks the precision to recognize our whole, inclusive identities. A lot of it is based in our history in medicine.

Fortunately, there is now a greater appreciation that race is a social concept, rather than a genetically bounded category, thanks to the genomic revolution. We know now that we, as a species, share 99.9% of our DNA with each other, and that our traits that are typically associated with race are not linked genetically to health-related genes.

There is a greater appreciation for the role of environmental, social and behavioral factors, their influence on health outcomes, and how they probably determine over 70% of what determines health, according to the Centers for Disease Control and Prevention. That exceeds the contribution made by genetics and even medical treatment.

Black Americans have higher rates of morbidity and mortality for COVID-19. Systemic inequities also bear out for Latinos and Indigenous Americans. Are racial inequities baked into the health care system?

Sadly, racism and bias are baked into most, if not all, of our institutions. We need to identify where they exist and then address and change them. I'm committed to that.

A recent Kaiser Family Foundation survey found that one in five Black Americans say they've experienced discrimination while seeking health care in a clinic.

That's a stark statistic, and it likely does reflect the experiences of Black Americans. I think that we as physicians are morally obligated to practice cultural humility -- the fact that we all carry unconscious biases. We all do. We have to become aware of that and approach it with a certain level of humble inquiry, questioning ourselves in how we're practicing medicine.

How do the murders of George Floyd, Breonna Taylor and many others, and the data you're talking about, meet this particular moment? Are we at an inflection point?

I think so. There is a greater interest in raising our collective awareness around these issues. I've also noticed that there is a concerted effort behind wanting to make curricular changes in medical school, so we are understanding how race and racism impacts health and health outcomes.

I'm seeing changes I've never witnessed before, happening throughout our institutions.It's really an important time.

Top image of Megan Mahoney, MD, with a patient by Steve Fisch. Family photos courtesy of Mahoney.

Read this article:

Biracial Stanford physician: We must look beyond race in medicine - Scope

Burrell College of Medicine and NMDOH to host free Halloween flu shot clinic – The Round Up

The New Mexico Department of Health partnered upwith the Burrell College of Osteopathic Medicine tooffer free flu shots for the publicon Oct. 31.

The event will behappeningata drive-thruclinic locatedat3501 Arrowhead Drive. Flu shots will be availablefor everyone from six months and abovefrom 8:00 a.m. to 12:00 p.m. All attendees are required to wear a mask.

According to David Daniels, disease prevention program manager from the New Mexico Department of Health, there is usually one event like this one per year which is organized by them. Daniels said that this kind of event has been going on for at least 10 years.

Due to COVID-19 and the importance of public health, this year they organized three separate drive-thru clinics. The first one was onOct. 17, another oneOct.24and the upcomingand last oneonOct.31. Thedrive through clinicsareusuallyheld onclosest Saturday to Halloween.

Were only going to do Boo to the Flu events for these dates that we had scheduled, but moving forward, we will have flu vaccines available at our public health office, so this is the one mass vaccination event for the year, Daniels said.

The New Mexico Department of Health recommends that everyone gets their flu shot during these timesspecially since COVID-19 is going around.Free vaccinesare availablethanks to government funds.

We realized that ss long as we can demonstrate what we are doing in the event of an emergency, we could get the community vaccinated for free, and thats what Boo to the Flu turned into, Daniels said.

In the event of a COVID-19 vaccine, the New Mexico Department of Health is more than ready to handle the distributionof said vaccineto theNew Mexico community.

Were looking to have our hospital partners that know how to do these events help us do some of this, Daniels said. At the health departmentwe do this already, with COVID testing, we have a similar process down so we could potentially vaccinate for COVID.

Daniels mentioned that the events have been of great success this year. The programeven ran out of shots to give during one ofthe clinics.Theevent held Oct. 17gathered 1,064 people while the one onOct. 24had 1,800attendeesintotal. Danielsencourages everyone who hasnt gotten their flu shot to attend this Saturday.

In the spirit of Halloween,health care providers at the event will be dressed up in costumes. Everyone who attends is encouraged to wear a costume of their own, especially all children attending.

The rest is here:

Burrell College of Medicine and NMDOH to host free Halloween flu shot clinic - The Round Up

Outlook on the Regenerative Medicine Global Market to 2025 – Impact of COVID-19 on the Market – GlobeNewswire

Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer's, Parkinson's and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global regenerative medicine market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, type, application and end user.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology 2.1 Objectives of the Study2.2 Stakeholders2.3 Data Sources2.3.1 Primary Sources2.3.2 Secondary Sources2.4 Market Estimation2.4.1 Bottom-Up Approach2.4.2 Top-Down Approach2.5 Forecasting Methodology

3 Executive Summary

4 Introduction4.1 Overview4.2 Key Industry Trends

5 Global Regenerative Medicine Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast

6 Market Breakup by Type6.1 Stem Cell Therapy6.1.1 Market Trends6.1.2 Market Forecast6.2 Biomaterial6.2.1 Market Trends6.2.2 Market Forecast6.3 Tissue Engineering6.3.1 Market Trends6.3.2 Market Forecast6.4 Others6.4.1 Market Trends6.4.2 Market Forecast

7 Market Breakup by Application7.1 Bone Graft Substitutes7.1.1 Market Trends7.1.2 Market Forecast7.2 Osteoarticular Diseases7.2.1 Market Trends7.2.2 Market Forecast7.3 Dermatology7.3.1 Market Trends7.3.2 Market Forecast7.4 Cardiovascular7.4.1 Market Trends7.4.2 Market Forecast7.5 Central Nervous System7.5.1 Market Trends7.5.2 Market Forecast7.6 Others7.6.1 Market Trends7.6.2 Market Forecast

8 Market Breakup by End User8.1 Hospitals8.1.1 Market Trends8.1.2 Market Forecast8.2 Specialty Clinics8.2.1 Market Trends8.2.2 Market Forecast8.3 Others8.3.1 Market Trends8.3.2 Market Forecast

9 Market Breakup by Region9.1 North America9.1.1 United States9.1.1.1 Market Trends9.1.1.2 Market Forecast9.1.2 Canada9.1.2.1 Market Trends9.1.2.2 Market Forecast9.2 Asia Pacific9.2.1 China9.2.1.1 Market Trends9.2.1.2 Market Forecast9.2.2 Japan9.2.2.1 Market Trends9.2.2.2 Market Forecast9.2.3 India9.2.3.1 Market Trends9.2.3.2 Market Forecast9.2.4 South Korea9.2.4.1 Market Trends9.2.4.2 Market Forecast9.2.5 Australia9.2.5.1 Market Trends9.2.5.2 Market Forecast9.2.6 Indonesia9.2.6.1 Market Trends9.2.6.2 Market Forecast9.2.7 Others9.2.7.1 Market Trends9.2.7.2 Market Forecast9.3 Europe9.3.1 Germany9.3.1.1 Market Trends9.3.1.2 Market Forecast9.3.2 France9.3.2.1 Market Trends9.3.2.2 Market Forecast9.3.3 United Kingdom9.3.3.1 Market Trends9.3.3.2 Market Forecast9.3.4 Italy9.3.4.1 Market Trends9.3.4.2 Market Forecast9.3.5 Spain9.3.5.1 Market Trends9.3.5.2 Market Forecast9.3.6 Russia9.3.6.1 Market Trends9.3.6.2 Market Forecast9.3.7 Others9.3.7.1 Market Trends9.3.7.2 Market Forecast9.4 Latin America9.4.1 Brazil9.4.1.1 Market Trends9.4.1.2 Market Forecast9.4.2 Mexico9.4.2.1 Market Trends9.4.2.2 Market Forecast9.4.3 Others9.4.3.1 Market Trends9.4.3.2 Market Forecast9.5 Middle East and Africa9.5.1 Market Trends9.5.2 Market Breakup by Country9.5.3 Market Forecast

10 SWOT Analysis10.1 Overview10.2 Strengths10.3 Weaknesses10.4 Opportunities10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis12.1 Overview12.2 Bargaining Power of Buyers12.3 Bargaining Power of Suppliers12.4 Degree of Competition12.5 Threat of New Entrants12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape14.1 Market Structure14.2 Key Players14.3 Profiles of Key Players14.3.1 Allergan PLC (AbbVie Inc.)14.3.1.1 Company Overview14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis14.3.2 Amgen Inc.14.3.2.1 Company Overview14.3.2.2 Product Portfolio14.3.2.3 Financials 14.3.2.4 SWOT Analysis14.3.3 Baxter International Inc.14.3.3.1 Company Overview14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis14.3.4 BD (Becton, Dickinson and Company)14.3.4.1 Company Overview14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis14.3.5 Integra Lifesciences Holdings Corporation14.3.5.1 Company Overview14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis14.3.6 Medtronic Plc14.3.6.1 Company Overview14.3.6.2 Product Portfolio 14.3.6.3 Financials14.3.6.4 SWOT Analysis14.3.7 Mimedx Group Inc.14.3.7.1 Company Overview14.3.7.2 Product Portfolio14.3.7.3 Financials 14.3.8 Novartis AG14.3.8.1 Company Overview14.3.8.2 Product Portfolio 14.3.8.3 Financials14.3.8.4 SWOT Analysis14.3.9 Osiris Therapeutics Inc. (Smith & Nephew plc)14.3.9.1 Company Overview14.3.9.2 Product Portfolio14.3.10 Thermo Fisher Scientific Inc.14.3.10.1 Company Overview14.3.10.2 Product Portfolio 14.3.10.3 Financials14.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ywnlq5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Continued here:

Outlook on the Regenerative Medicine Global Market to 2025 - Impact of COVID-19 on the Market - GlobeNewswire

Beat AML Master Clinical Trial Shows Promise for Precision Medicine in the Treatment of AML – Cancer Network

Patients who participated in the Beat AML Master clinical trial were found to have superior outcomes with precision medicine, compared to patients with acute myeloid leukemia (AML) who opted for standard chemotherapy treatment, according to a study published in Nature Medicine.1

Overall, the study demonstrated that a precision medicine therapy strategy in AML is feasible within 7days of sample receipt and before treatment selection, allowing patients and physicians to rapidly incorporate genomic data into treatment decisions without increasing early death or adversely impacting overall survival (OS).

The study shows that delaying treatment up to seven days is feasible and safe, and that patients who opted for the precision medicine approach experienced a lower early death rate and superior overall survival compared to patients who opted for standard of care, corresponding author John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research of The Ohio State University, said in a press release.2 This patient-centric study shows that we can move away from chemotherapy treatment for patients who wont respond or cant withstand the harsh effects of the same chemotherapies weve been using for 40 years and match them with a treatment better suited for their individual case.

In the ongoing Beat AML trial, researchers prospectively enrolled untreated patients with AML who were60 years or older with the aims of providing cytogenetic and mutational data within 7days of the sample receipt and before treatment selection, followed by treatment assignment to a sub-study based on the dominant clone. In total, 487 patients with suspected AML were enrolled in the study and 395 were deemed eligible for analysis.

The median age of the participants was 72 years (range 60-92 years). Overall, 374 patients (94.7%) had genetic and cytogenetic analysis completed within 7days and were centrally assigned to a Beat AML sub-study, while 224 (56.7%) were enrolled on a Beat AML sub-study. The remaining 171 patients elected to receive either standard of care (n = 103), investigational therapy (n = 28), or palliative care (n = 40). Moreover, 9 patients died before treatment assignment.

Demographic, laboratory, and molecular characteristics were not found to be significantly different between patients on the Beat AML sub-studies and those receiving standard of care (induction with cytarabine+daunorubicin [7+3 or equivalent] or hypomethylation agent).

However, 30-day mortality was less frequent, and OS was significantly longer for patients enrolled on the Beat AML sub-studies versus those who elected to receive standard of care. The median OS for patients included in the Beat AML trial was 12.8 months versus 3.9 months for patients opting for standard of care.

To date, the trial has now screened more than 1000 patients at 16 cancer centers. The data presented herein represents patient enrollment during a slice of time between November 17, 2016 and January 30, 2018.

The study is changing significantly the way we look at treating patients with AML, showing that precision medicine, giving the right treatment to the right patient at the right time, can improve short and long-term outcomes for patients with this deadly blood cancer, Louis J. DeGennaro, PhD, president and CEO of the Leukemia & Lymphoma Society (LLS), the conductor of the trial, said in the release. Further, Beat AML has proven to be a viable model for other cancer clinical trials to emulate.

Recently, LLS launched itsBeat COVIDtrial, which leveraged the Beat AML infrastructure to quickly pivot to treat patients with blood cancer who are infected with the coronavirus disease 2019 (COVID-19) virus. The trial is testing the drug acalabrutinib (Calquence), which is currently approved to treat several types of blood cancers. The trial is open to patients diagnosed with all types of blood cancers.

Additionally, LLS is also planning other precision medicine trials modeled after Beat AML, including LLS PedAL, a global precision medicine trial for children with relapsed acute leukemia, currently on track to launch in summer 2021, and Stop MDS, a master trial for patients withmyelodysplastic syndromes.

References:

1. STUDY IN NATURE MEDICINE SHOWS SUPERIOR OUTCOMES FOR PATIENTS IN LLS'S PARADIGM-SHIFTING BEAT AML CLINICAL TRIAL [news release]. Rye Brook, NY. Published October 26, 2020. Accessed October 28, 2020. https://www.lls.org/news/study-in-nature-medicine-shows-superior-outcomes-for-patients-in-llss-paradigm-shifting-beat-aml-clinical-trial?src1=182886&src2=

2. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature Medicine. doi: 10.1038/s41591-020-1089-8

See the original post:

Beat AML Master Clinical Trial Shows Promise for Precision Medicine in the Treatment of AML - Cancer Network

Beware the Trojan Horse of Integrative Medicine | Office for Science and Society – McGill Newsroom

The story of the Trojan horse is well known: the Greeks allegedly delivered to the city of Troy a massive wooden horse, which the Trojans mistook for a gift and pulled inside their city. At night, this hollow horse released a band of Greek men who had been hiding inside of it, and they opened the city gates so that their army could strike the final blow in the Trojan War.

The concept of integrative medicine has gained in popularity since it was coined by Dr. Andrew Weil in 1994 and it is important to recognize it as the Trojan horse that it is. Although the metaphor usually implies deception, many fans of integrative medicine promote this gift horse without misleading intentions, but the damage may well be the same.

The claim at the heart of integrative medicine is that conventional medicine is not enough and that so-called complementary and alternative medicine (CAM) is also insufficient, but that by integrating the two, patients get the best of both worlds. Medicine is accused of being hyper-focused on disease and on the use of pharmaceuticals, failing patients with chronic illnesses. CAM is positioned as the answer to this, the yang to conventional medicines yin to yield a complete, holistic perspective.

On its surface, the CAM half of integrative medicine looks wonderful. We are usually told it involves nutrition and exercise. Similarly, proponents of integrative medicine claim its added value is in holism, meaning focusing on the whole person. Strangely though, as has been argued by many people, conventional medicine at its best is focused on the whole person. But integrative medicines seductive, superficial messaging does not end there.

This Trojan horse has been making major in-roads inside of academic hospitals, and it moves on four wheels: the appeals to nature, antiquity, authority, and popularity. Hospital directors and patients alike are told that integrative medicine prioritizes natural treatments... without mentioning that synthesized products are not necessarily harmful and natural ones, not necessarily harmless (or useful). They are told that many of these interventions, like acupuncture, have been used for a long time... just like bloodletting was in ye olden days. They are told that many serious university hospitals, like Johns Hopkins, Duke, and Yale, are already offering integrative medicine... but keeping up with the Joneses is no substitute for a critical appraisal of the body of evidence. And they are told that many, many people are clamouring for these therapies. Market forces being what they are, the Trojan horse rolls into town and we may wonder what pours out of it.

Inside the Trojan horse of integrative medicine, painted in the colours of nutrition and exercise, we find unproven and disproven remedies like homeopathy, the 200-year-old philosophy that claims that the more a substance is diluted, the stronger it becomes. We find Reiki and other energy healing interventions, which pretend that hands-off massages of an undiscovered force field around the body can provide healing. We find poorly regulated herbal remedies, problematic therapies like acupuncture, and things like reflexology, where a foot massage can somehow help your stomach heal itself. The horse also contains more benign interventions, like art therapy and massages, but the majority of CAMs contribution puzzles the mind. These often pre-scientific folkloric therapies often lack plausible mechanisms. Given our extensive knowledge of biology, it makes no sense for the entire human body to be represented on the sole of our feet (see reflexology). Given our extensive knowledge of chemistry, it makes no sense for vast dilutions that leave behind no trace of the ingredient to work (see homeopathy). Yet proponents often throw their hands up when confronted with this and simply claim that it works, how ever it may work.

Universities can easily fall under the spell of integrative medicine because of what I would call the two towers. Imagine two towers that visually represent the evidence we have for conventional medicine and for complementary and alternative medicine, things like homeopathy and Reiki. The conventional medicine tower has an old foundation and is continually being extended and repaired with better materials. By comparison, the CAM towers foundation is made of cheap, imitation material, and while theres a shell that gives it its full height, the bricks have not been laid yet. But the structure is draped in a banner that illustrates what the tower will look like when finished. From a distance, both towers appear similar. Same height, same look. But when you get closer to the CAM tower, you notice how grossly incomplete it is. Dont worry, you are told, what we have so far is very promising and we will keep building it. This slogan never goes away. The CAM tower will always be sold as promising, year after year, convincing many people to invest in it.

Studies of ear acupuncture, craniosacral therapy, homeopathy and many other complementary interventions are usually small, poorly done, and encouraging. When rigorous trials are completed, they fail to demonstrate efficacy, which leads CAM proponents to return to smaller studies and extract hopeful results from those. This tower of promising results can then be presented to academic health centres by philanthropists who believe acupuncture or homeopathy cured them, and their generous donations can lead to the creation of integrative medical centres within these hospitals. Impressive consortia are created to advocate for integrative medicine and to put pressure on medical school curricula to pull the Trojan horse in.

There are clear harms to this. Obviously, if I were to argue that because astronomy is insufficient, it needs to hold hands with astrology in university faculties, it would be easier to see the potential for intellectual harm. Similarly, I have seen Canadians elevating Indigenous ancestral knowledge to the same level as science and asking for its integration into medicine, without testing these claims with the most rigorous tools we have, and I find this equally troublesome

Theres also the financial harm to selling invalid therapies to patients, but perhaps an even bigger eye-opener on the subject of harm is vaccination. Integrative medicine frequently does not embrace immunization, one of the most important public health interventions we have. Dr. Daniel Neides, former director of the Cleveland Clinic Wellness Institute, infamously wrote a furious anti-vaccination screed in 2017 on the website Cleveland.com. Meanwhile, a survey completed by 290 members of the American Board of Integrative and Holistic Medicine revealed them to be more likely than their conventional counterparts to believe misinformation about vaccines (e.g. alternative schedules, toxicities, link to autism). Chiropractors, whose practice is often rolled into integrative medicine, are notorious for harbouring a significant percentage of antivaxxers; ditto for naturopaths. Given how many CAM disciples worship at the altar of Mother Nature and see toxins everywhere, a vote for integrative medicine often risks bolstering unnecessary vaccine hesitancy.

If you are caught looking this Trojan horse in the mouth, the most likely retort you will hear is that conventional medicine has problems. Yes, it does. It is true that medicine does not offer great solutions to many chronic conditions, chief among them chronic pain. Some of its solutions, like opioids, have also caused significant harm because of misplaced economic interests. But the medicine tower gets fixed. Moldy parts are extruded and replaced. Meanwhile, the CAM tower remains deeply flawed and mostly illusory. The bricks are coming, we are told, and soon we will have the proof we need.

If I may bring one more metaphor to this crowded landscape, it would be Dr. Ben Goldacres pearl of wisdom. Problems in aircraft design, he says, do not mean that magic carpets can actually fly. As the Trojan horse of integrative medicine knocks on the doors of our institutions, we must remember that what we need is not a hollow prize with a corrupting cargo; we need to keep fixing the real tower.

Take-home message:-Integrative medicine is a philosophy that advocates for the integration of conventional medical care with numerous complementary and alternative therapies, like Reiki and homeopathy- The evidence for these complementary therapies is often lacking but they keep being sold as a promising solution to the problems of real medicine- Its important to remember that just because there are problems with airplanes, the solution is not to switch to flying carpets

@CrackedScience

Read the rest here:

Beware the Trojan Horse of Integrative Medicine | Office for Science and Society - McGill Newsroom

Runnin’ with Rani: Applying sports medicine in the workplace – West Hawaii Today

Its no surprise that neck, shoulder, and back pain are common complaints among athletes who are constantly training and racing as they push their bodies to the limit. Just ask anyone who has taken a six-hour bike ride to Hawi about the stiffness and soreness they feel afterwards. How about a distance swimmer or a runner training for a marathon?

Yes, we all know the feeling. While having a proper bike fit, stretching and daily foam rolling can help to alleviate common nagging symptoms, most still end up seeing a professional like a chiropractor, massage and physical therapist for relief.

Now, with more people having increased screen time to work, learn and communicate remotely due to COVID-19, these very same symptoms neck, shoulder and back pain have caused an uptick in the number of patients walking through the door of Dr. James Stanleys quaint chiropractic office. And I am one of them.

I have been seeing Dr. Stanley for more than a decade to treat various imbalances associated with running and riding my bike. However, over the last three weeks my visits have been linked to symptoms primarily caused by a drastic increase in sitting while viewing a laptop screen.

I caught up to the busy doctor who kindly shared some sound advice on how to improve ones virtual setup at home or in the office, the importance of allowing your eyes frequent breaks from the screen, and the benefits of exercise to improve mood and motivation.

Q: With more people having to work, learn, and communicate virtually on a daily basis due to COVID-19, what physical ailments do you find are common among teleworkers?

I find that with the COVID -19 pandemic I am seeing a much greater incidence of posture and stress related musculoskeletal complaints in my practice. Common ailments such as headaches, carpal tunnel, piriformis syndrome, sciatica, chronic hip flexor shortening are definitely increased. Upper neck, upper back and lower back are common areas of increased muscle tension and subsequently joint dysfunction with prolonged sitting activity.

When you combine this activity with a poor ergonomic work environment such as a dining table or worse, the results are not great. I have witnessed increased complaints of eye strain with the demands of our teachers setting up learning systems. Some of the complaint is due to simply excessive screen time but some is due to ergonomics of the work environment. Often the workers are setting up multiple screens that are not at an ideal height or positioned too far to one side of their bodies.

Having proper external monitors is critical to surviving the prolonged online activity. Eliminating the need to stare at a laptop monitor is a great first step to improving endurance in this work environment. Adding peripherals such as an external keyboard and mouse are very helpful to achieving a proper posture.

Q: How do these physical ailments negatively affect athlete performance?

Athletic performance is negatively impacted by the effects of chronically tight and imbalanced musculature. Shortened hip flexors, inactivated glutes are just some of the imbalances that can lead to poor form and increase injury in running and other sports. Tightness in the calves can lead to Achilles and plantar fascial issues.

Q: What causes digital eye fatigue and how can one remedy this?

Reading from a screen places unusual demands on the visual system. Minor visual conditions that are not well managed can be more evident. Differences in contrast, brightness and viewing angle from reading a physical print are some of the factors at play.

Improving seating posture and viewing angle can help. Placing the top of the screen at eye level. Make sure your feet are flat on the ground, your back is supported by the chair and your chest is high. When you are in a proper posture your shoulders should not roll forward and your head should feel as if it is floating on your upper body. This head, shoulder and chest posture is also an important part of good running form. Have you heard the phrase Run tall in your shoes?

Q: What can people do to reduce the physical strain from sitting for long periods of time?

Break it up! Try not to spend more than 30 minutes in one position. Get up and walk around the room or stretch lightly then return to the activity. Focus on stretches for hip flexors, air squats to activate your gluteal, shoulder rolls forwards and backwards to mobilize your shoulder and upper thoracic spine. Periodically look outside or even across the room to change your focus distance.

For your wrists and hands, shake them out. Stretch each hand in flexion and extension with the other hand. Place your main monitor as close to center as possible. Bring your mouse and keyboard closer to your body.

Q: Due to current social distancing guidelines and many sporting events canceled, people find themselves more sedentary than ever. What advice can you give?

Lucky we live Hawaii! Get outside. Body weight exercises are a fantastic way to substitute for gym time. I think walking is one of the most underrated exercises. Set a time goal of 20-30 minutes per day and go for a walk. The motivation you will gain from just that activity will improve mood and motivation to do more. It is also a time to set your goals for the post pandemic future. Make yourself some short term actionable physical training goals and some long-term vision goals such as that race you want to do someday.

About Dr. James Stanley

Originally from Washington state, Dr. Stanley holds a doctor of chiropractic degree (DC) and graduated with honors from Palmer College of Chiropractic in Iowa. He has been in practice for 31 years, nineteen of which have been in Hawaii.

Dr. Stanleys practice centers around a functional approach to rehab and performance with emphasis on mobility, ergonomics, balance and strength. He also has additional certification in extremity joint manipulation and management.

Dr. Stanley runs for fitness and other personal interests include songwriting and performing with an original rock band The 1201. His chiropractic practice is located in Pines Plaza of lower Nani Kailua Drive (75-240 Nani Kailua Drive, Suite 3). For more information call 326-9229.

See more here:

Runnin' with Rani: Applying sports medicine in the workplace - West Hawaii Today

Next-gen Precision Medicine Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2018 2028 – Aerospace Journal

Global Next-gen Precision Medicine Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Next-gen Precision Medicine industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/25714

For competitor segment, the report includes global key players of Next-gen Precision Medicine as well as some small players.

Key participants operating in the Next-gen precision medicine market are: F. Hoffmann-La Roche AG, Illumina, Inc, Thermo Fisher Scientific Inc, QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Eli Lilly And Company and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Sample Report @ https://www.persistencemarketresearch.co/samples/25714

Important Key questions answered in Next-gen Precision Medicine market report:

What will the market growth rate, Overview, and Analysis by Type of Next-gen Precision Medicine in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Next-gen Precision Medicine market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Next-gen Precision Medicine market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/25714

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Next-gen Precision Medicine product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Next-gen Precision Medicine , with price, sales, revenue and global market share of Next-gen Precision Medicine in 2019 and 2015.

Chapter 3, the Next-gen Precision Medicine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Next-gen Precision Medicine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Next-gen Precision Medicine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Next-gen Precision Medicine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Continued here:

Next-gen Precision Medicine Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2018 2028 - Aerospace Journal

Nagorno-Karabakh: UK to provide food and medicine to people affected by the conflict – GOV.UK

Thousands of people affected by the Nagorno-Karabakh conflict will receive urgent medical supplies, food and safer shelters from a new UK aid package, announced today by the Foreign Secretary Dominic Raab.

The conflict escalated on 27 September. Since then, tens of thousands of people have been forced to flee their homes, with growing numbers of civilian casualties and damage to homes and vital infrastructure.

Now much-needed medical supplies, including dressing kits and bandages, will be provided for civilians caught up in the crisis through a new 1 million UK aid package, in response to an appeal by the International Committee of the Red Cross (ICRC). People injured in the fighting, including children caught in the crossfire, will receive life-saving treatment at health facilities or from emergency responders supported by the ICRC.

Many of those affected have limited access to food and other essentials, and UK support will provide blankets, food parcels and basic hygiene items to vulnerable communities near to the fighting.

Foreign Secretary Dominic Raab said:

Todays UK aid package will help deliver vital food, medicine and urgent healthcare to those affected by the Nagorno-Karabakh conflict. We continue to urge both sides to engage with the OSCE Minsk group and seek a peaceful, negotiated, political solution which the people of the region so desperately need.

ICRC Regional Director for EURASIA, Martin Schuepp said:

The ICRC is most grateful to the UK for its contribution to the ICRCs response in the region. The high-quality funding the ICRC receives from its donors, including the UK, enables the ICRC to deliver neutral, impartial and independent action to those affected by armed conflict and other situations of violence.

UK support will also help to improve the quality of often overcrowded shelters by installing or improving water tanks and toilets. It will also ensure the shelters are suitably equipped to keep warm as the regions bitter winter approaches.

The UK, along with Canada, has repeatedly called for both sides to work towards a peaceful, political resolution to the conflict through the Organization for Security and Co-operation in Europes (OSCE) Minsk process and has expressed its full support for the work of the Minsk Group.

The new funding is in addition to our core funding to ICRC. In recent years, the UK has been the second largest donor globally to the ICRC, helping them to respond quickly to situations of armed conflict.

The ICRC is an independent, neutral organisation ensuring humanitarian protection and assistance for victims of armed conflict and other situations of violence.

See more here:

Nagorno-Karabakh: UK to provide food and medicine to people affected by the conflict - GOV.UK

Singapore has potential to be centre for research in Ayurvedic medicines for diabetes: Experts – The Tribune India

Singapore, October 31

Singapore, with growing number of pharmaceutical multinationals, has the potential of becoming a centre for further research in Ayurvedic medicines for the benefits of diabetic patients globally including more than 100 million in India, health experts said on Saturday.

More Ayurveda medicine research can be done in Singapore to establish the phytochemical components of such herbs to enhance the efficacy in herbal production and storage, said Charles Chow, managing director of East-West Group, a multi-disciplinary business consultancy.

Export-oriented Ayurvedic pharmaceutical companies from India can be a good source of higher-grade herbs for use in research work here, added Chow.

Treatment processes can be administered by prescribed ayurvedic practitioners approved by the health authorities in Singapore, according to Chow, who pointed out the growing use of ayurvedic medicine and popularity of its practioners in Singapore.

Perhaps standard procedures already proven in India can be replicated in Singapore during the research work and trials, he added, underlining the need to further the administration of Ayurveda medicines to diabetics.

Ayurveda medicines can be taken as an alternative way to control diabetes, or as a complement to medication (e.g. insulin or metaformin) used by Western medicine, to prevent deterioration that result in more complications, he elaborated. Chow is working with ALR Technologies Inc (ALRT), a 1988-listed company in the United States, which is offering its diabetes solution for monitoring blood glucose levels. ALR Technologies has relocated to Singapore for the Asian markets including India.

ALRT Diabetes Solution was launched in Singapore on Saturday.

We will soon be exploring ways to reach out to the world's largest markets such as India, he said, pointing to the growing number of wealthy people turning diabetic due to rich diets.

Chow estimates 450 million people suffering from diabetics worldwide, half of which are in Asia.

ALRT is collaborating with Diabetes Singapore to develop a diabetes management programme for its current and prospective members. Diabetes Singapore, a charity founded in 1971, is a member of the International Diabetes Federation, Western Pacific Region.

The number of Singapore residents living with diabetes is projected to increase to close to one million by 2050 if nothing is done, said Satyaprakash Tiwari, Executive Director of Diabetes Singapore.

The latest edition of the International Diabetes Federation's Diabetes Atlas lists Singapore as having the highest diabetes prevalence amongst developed countries, overtaking the US, Japan, Finland, Taiwan and Hong Kong, said Tiwari. PTI

Read more:

Singapore has potential to be centre for research in Ayurvedic medicines for diabetes: Experts - The Tribune India

Dr. Tap on the Rise of Precision Medicine in Sarcoma – OncLive

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the rise of precision medicine in sarcoma.

The treatment landscape of sarcoma is rapidly evolving with regard to advances in science, technology, and biology, says Tap.

For example, the explosion of immunotherapy options has been transformative across multiple tumor types, Tap explains. Other areas of significant cancer research include epigenetics, cellular signaling, and DNA damage response patterns.

Sarcoma is a prime target to implement precision medicine, as the disease is associated with numerous genomic aberrations, Tap says.

Moreover, the field is moving toward tailoring treatments to individual disease subtypes based on genomic and epigenetic abnormalities rather than treating all patients with sarcoma with the same one-size-fits-all approach, concludes Tap.

Read the original post:

Dr. Tap on the Rise of Precision Medicine in Sarcoma - OncLive

Choi elected to National Academy of Medicine | Cornell Chronicle – Cornell Chronicle

Dr. Augustine M.K. Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.

The academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.Choi is among 100 new members elected to the body in 2020, announced Oct. 19 in conjunction with NAMs annual meeting.

I am deeply honored to be elected by my peers to the National Academy of Medicine and to join the ranks of such a distinguished group of physicians and scientists, Choi said. The academys recognition of my research is truly humbling, and I would like to thank my colleagues and my mentees whose collective efforts have advanced the field of pulmonology. Im also grateful for the academys recognition of my commitment to elevating diversity, equity and mentorship in academic medicine. I look forward to continuing this work and sharing my expertise and service with NAM.

Dr. Choi is an exceptionally talented physician, scientist and leader whose contributions to pulmonary and critical care medicine have made a lasting impact on the fields of medicine and science, said Martha E. Pollack, president of Cornell University. I congratulate Dr. Choi on his election to the National Academy of Medicine.

Established in 1970, the National Academy of Medicine is an independent organization that works to address critical issues in health, science, medicine and related policy, and is part of the larger National Academies of Sciences, Engineering and Medicine (NASEM). New members are elected annually by current members. NAM now counts more than 2,300 active members around the world. As part of their election, new members commit to volunteer their service in NASEM activities.

An international authority in pulmonary and critical care medicine, Choi has pioneered research involving the use of gaseous carbon monoxide to treat human diseases, including sepsis and pulmonary fibrosis, as well as non-pulmonary diseases.

In addition to more than 375 publications and multiple National Institutes of Health grants, Choi has received numerous honors and awards. These include the Ho-Am Prize in Medicine, often referred to as the Korean equivalent of the Nobel Prize, and the 2015 J. Burns Amberson Lecture, which recognizes a career of major lifetime contributions to pulmonary research. He is a member of the American Society of Clinical Investigation and the Association of American Physicians.

A renowned leader in academic medicine, Choi has elevated diversity and mentorship to pillars of Weill Cornell Medicines mission, alongside patient care, research and education. Choi has launched several programs and initiatives to foster a culture of diversity and inclusion in medicine, which include establishing the Office of Diversity and Inclusion, the Office of Institutional Equity, and Diversity Week, an annual event that showcases cutting-edge research and initiatives focused on enhancing diversity and reducing healthcare disparities at Weill Cornell Medicine and nationwide.

Choi has also built a strong culture of mentorship through initiatives like the institution-wide Mentoring Academy, a JumpStart program to provide financial support and mentorship to early-career scientists, and an annual faculty award to recognize excellence in mentoring.

Choi is an enthusiastic champion of advancing equity in health care and supporting aspiring doctors and scientists mental health and well-being. In 2019, he spearheaded an expansion of Weill Cornell Medicines scholarship program to offer debt-free medical education for all students who qualify for financial aid. Choi also conceptualized and hosted the inaugural National Conference on Medical Student Mental Health and Well-Being, believed to be the first comprehensive, multidisciplinary forum to examine the mental health needs of medical students.

Choi received his bachelors degree in 1980 from the University of Kentucky and his medical degree in 1984 from the University of Louisville. He completed his internship and residency in internal medicine at Duke University and a fellowship in pulmonary and critical care medicine at Johns Hopkins Medicine.

Recruited to Weill Cornell Medicine in 2013, Dr. Choi served as the Sanford I. Weill Chairman and professor of medicine in the Joan and Sanford I. Weill Department of Medicine and as physician-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center until his appointment as dean in 2017.

Elaine Meyer is a freelance writer for Weill Cornell Medicine.

Read the original here:

Choi elected to National Academy of Medicine | Cornell Chronicle - Cornell Chronicle

Oakland University William Beaumont School of Medicine names Weimann director of Philanthropy – News at OU

Oakland University William Beaumont School of Medicine has named Claus Weimann director of Philanthropy.

Weimann joined OUWB on Aug. 3. In his new role, Weimann is a member of the Leadership Team of OUWB Stephan Sharf Dean Duane Mezwa, M.D., as well as the OUWB Advisory Board.

His primary responsibilities are overseeing and directing the fundraising activities for OUWB, primarily to help secure financial support to fund scholarships for the schools students.

Most recently, Weimann worked at University of Michigan-Flint, where he was a special advisor to the universitys provost and a fundraiser.

Weimann, who has spent his career in development and fundraising, said hes excited about his new role at OUWB.

I feel like OUWB really has momentum and an American entrepreneurial spirit that I really like and appreciate, he said. Things are not put in stone from an institution that is 200-plus years old there are opportunities to still be a pioneer and build things.

In fundraising we call that grass roots, he added. I really like that thats where I feel at home.

That really changed my life

Weimann, originally from northern Europe, earned two degrees in International Business: a bachelors from AKAD University of Hamburg and a masters from AKAD University of Dusseldorf.

He began his career in development and fundraising in Cologne, Germany with an NGO following what he describes as a life-changing experience.

That experience consisted of eight months he spent living in the slums of El Salvador, where he taught English and sports at a school sponsored by the European Union.

I loved it, he said. I loved seeing how the euros and dollars that arrived really made a huge change.

That really changed my life, he added.

Upon his return to northern Europe, Weimann cold-called the person in charge of the program (Mano Amiga) he had worked for in El Salvador and essentially asked if he could get involved with fundraising.

He said I need somebody like you right herecome here next week, he said. I made the four-hour drive to Cologne and thought it was going to be a little interview, but he actually approached me to work for him. He said he wanted people who are authentic, went through (the experience in El Salvador), and can tell the story. It was totally mind blowing for me.

Weimann

Weimann said he learned a lot during his experience working for Mano Amiga and it opened doors for more opportunities.

Subsequent to Mano Amiga, Weimann served as director of fundraising at Cologne Business School and director of development at St. Augustin University.

In 2015, Weimann, along with his wife and children, moved to Michigan. Weimann was hired as a senior major gift officer at University of Michigan-Flint. He would go on to become associate director of Education Abroad and Corporate Development Officer.

All about supporting students

Weimann said he was drawn to OUWB by the schools commitment to being a collaborative, diverse, inclusive, and technologically advanced learning community, as outlined in its mission statement.

OUWB states that theyre the school that cares about individuals and I really like that its just phenomenal to be part of that, Weimann said.

Weimann said he has seen the difference such levels of care can make in the lives of people who need it most, including one of his children who has struggled with juvenile arthritis.

To see how a physicians empathy and caring can change the world and light it up for a young child really sparked my interest in putting my full passion into supporting students that want to be doctors, he said.

With regard to immediate goals at OUWB, Weimann said its all about supporting students.

I want to talk about the great stories that happen, the connections we build, how students are supported, and the very exciting programs in the pipeline, he said.

Weimann said he also hopes to be able to have helped a wider swath of people understand more about the OUWB community and why they should consider supporting the school.

In a year, I really hope to say that we have gained supporters and ambassadors of the many people we connected with because we inspired them with the work we are doing at OUWB, he said.

For more information, contact Andrew Dietderich, marketing writer, OUWB, atadietderich@oakland.edu.

Follow OUWB onFacebook,Twitter, andInstagram.

NOTICE: Except where otherwise noted, all articles are published under aCreative Commons Attribution 3.0 license. You are free to copy, distribute, adapt, transmit, or make commercial use of this work as long as you attribute Oakland University William Beaumont School of Medicine as the original creator and include a link to this article.

View post:

Oakland University William Beaumont School of Medicine names Weimann director of Philanthropy - News at OU

A new push to remove race-based assessments in medicine – BetaBoston

And in September, Senator Elizabeth Warren of Massachusetts and three other members of Congress called on the Department of Health and Human Services to investigate their use, warning that they risk embedding racism into medical practice.

Some medical institutions have stopped using race corrections in some tests. MGH and Brigham and Womens Hospital, for example, no longer adjust the results of a popular test for kidney functions, called eGFR. Critics worried the adjustment had tended to make kidney functions of Black patients look better, possibly concealing genuine problems and causing dangerous delays in needed medical care. Last week, a new study from Brigham and Womens Hospital concluded that eliminating race correction in kidney disease tests would qualify up to one in every three Black patients for more advanced care and that might result in more effective treatment of the disease.

There have been several reports of computer algorithms that produce racially biased results, such as facial recognition programs that can accurately identify white people, but not Black people. Earlier this year, a Black man in Michigan was arrested after facial recognition software falsely identified him as a criminal suspect. Such problems are usually a byproduct of the software development in this case, using too few photos of Black people to train the software to recognize dark-skinned faces.

Racial corrections for medical diagnostic tests were created on purpose. Consider the spirometer, used to measure lung capacity. The devices often require doctors to enter the race of the patient prior to the test, based on research dating back as far as the 19th century that indicates Black people have lower lung capacity than white people.

Other examples include an algorithm used to estimate the risk to the health of a pregnant woman planning to give birth vaginally, if she has previously undergone a caesarean birth. The race-adjusted algorithm predicts that vaginal birth is more dangerous for Black and Hispanic women than for white women. But for most women, vaginal deliveries result in fewer complications and faster recovery times. Vyas speculates that the algorithm may discourage doctors from offering vaginal deliveries to women of color, who already face a higher rate of maternal mortality.

The problem, according to Vyas, is that doctors and scientists are treating race as a clear-cut biological reality when it isnt. Research in population genetics has shown that apart from features such as skin color and hair texture, theres not that much difference genetically among people of different races. And the differences are bound to diminish even further, as interracial marriage becomes routine in the United States.

We know that race is not a biologic category, said Vyas. Its not genetic. Its a social construct.

Still, a variety of tests appear to show real differences between Black and white patients. The race correction for eGFR kidney tests was developed after large-scale research studies found that the test tended to underestimate kidney function in Black people.

Another example of the biology vs. environment tension involves the coronavirus. In a new paper in the Journal of the American Medical Association, researchers from the Mount Sinai School of Medicine reported that a gene associated with higher risk of contracting COVID-19 is more commonly found in the nasal tissues of Black people than white people. This genetic difference could help explain why such a high percentage of Black people in the US get infected.

But that doesnt prove that race is the reason. Vyas argues scientists should look for other explanations, such as the effects of systemic racism. For example, Black people are more likely to live in poverty, which exposes them to greater health risks. Vyas also said the psychological stress of coping with constant racism could affect the health outcomes of Black patients.

"Its not okay to just mention race without talking about racism, Vyas said.

The lead authors of the Mount Sinai study take note of this too, arguing that environmental and social factors play a role in the activation of genes. This could explain why Black people are more vulnerable to COVID-19.

Even a physician who helped develop the race-corrected algorithm for kidney tests agreed the practice has its limitations. But Lesley Inker, director of the Kidney and Blood Pressure Center at Tufts Medical Center, cautioned that failing to take race into account could also lead to faulty diagnoses in some cases.

For example, diabetes is the number-one cause of kidney failure among Black people. But because of potential side affects, current medical practice advises not administering two of the most effective drugs for diabetes to patients with low eGFR scores. Removing race correction from the kidney test would lower the scores of Black patients and make some of them ineligible for diabetes drugs that could help save their kidneys.

This is complex, and theres lots of pros and cons and balancing acts which should be considered prior to acting, Inker said.

Inker warns that giving up on these corrections too quickly might be dangerous. For instance, cardiologists have recently adopted a new way of assessing heart disease risk that takes race into account. For years, doctors have relied on data from a massive study of heart disease in Framingham, which began in 1948 and continues to this day. But the population of that study is overwhelmingly white. Now doctors supplement that data with an algorithm based on data from thousands of Black patients, and have found that the new approach is better at providing early warning of heart disease in Black people.

Melissa Simon, who heads the Center for Health Equity Transformation at Northwestern University Medical School in Chicago, said doctors need more data to understand the different health outcomes between Black and white people. In 2015, the National Institutes of Health launched a Precision Medicine Initiative that hopes to use genetic data and detailed information about a patients lifestyle and habits to determine the ideal course of treatment for each individual. Simon hopes that kind of highly personalized medicine could eliminate the need for race-based diagnostics altogether.

Updated with a new study on race correction in kidney disease tests.

Hiawatha Bray can be reached at hiawatha.bray@globe.com. Follow him on Twitter @GlobeTechLab.

Read the original:

A new push to remove race-based assessments in medicine - BetaBoston

MEDIA ADVISORY: Stony Brook Medicine Partners With Nassau & Suffolk County To Discuss the Importance of Getting Your Flu Vaccine – Stony Brook…

Stony Brook Medicine Media Contact: Kali Chan

Email: Kali.Chan@stonybrookmedicine.edu

Cell Phone: 631-487-4092

Stony Brook Medicine Partners With Nassau & Suffolk County To Discuss the Importance of Getting Your Flu Vaccine

WHEN:

Tuesday, October 20, 2020 from 7pm 8pm

WHAT:

Long Island is entering a critical flu season with a potential spike in COVID-19 expected in the fall and winter months. Populations with traditionally low flu vaccination rates, such as African-Americans, Native Americans and Hispanic/Latino populations, need to be informed about why getting the flu vaccine is especially important this year. Getting a flu vaccine will not protect against COVID-19, but the flu vaccine reduces the risk of flu illness, hospitalization and death. It also saves healthcare resources to care for patients with COVID-19 at a time when hospitals may be near or over capacity.

This Tuesday, October 20 join trusted health experts and Health Commissioners from the Suffolk and Nassau County Departments of Health, for a FREE Zoom webinar The Flu and You: What You Need to Know from 7 to 8 PM. They will answer your questions about the flu vaccine and provide sound advice for maintaining your and your familys health during this unprecedented public health crisis, with a potential second wave of coronavirus cases this winter.

PRESENTORS:

Please submit questions for speakers in advance at: stonybrookmedicine@stonybrookmedicine.edu

Register for this FREE Zoom Webinar at bit.ly/sbmflu

View post:

MEDIA ADVISORY: Stony Brook Medicine Partners With Nassau & Suffolk County To Discuss the Importance of Getting Your Flu Vaccine - Stony Brook...

New Research from Reproductive Medicine Associates Demonstrates Commitment to Science, Success, and Support of Hopeful Infertility Patients Trying to…

BASKING RIDGE, N.J., Oct. 19, 2020 /PRNewswire/ -- Reproductive Medicine Associates of New Jersey (RMA New Jersey), world-renowned leaders in the field of infertility treatment and research, will present over 30 clinical abstracts at the ASRM 2020 meeting including data from the PROV-ET Trial which investigated the predictive value of an aneuploid diagnosis with PGT-A and the impact of trophectoderm biopsy, a finalist for the 2020 ASRM Prize Paper Award.

"From the United States to Spain to the UK and all around the world, I'm incredibly proud of our research teams at IVIRMA and the work presented at ASRM," said Dr. Richard T. Scott, Jr., CEO of IVIRMA Global. "While last year was a tremendous year for our research team winning four awards at the ASRM, we haven't let up in 2020. For us, it's about advancing the field one question and one patient at a time, all the time."

Dr. Emre Seli, Chief Scientific Officer at IVIRMA Global and Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, highlighted the scope of the work presented at the 2020 ASRM Meeting, "IVIRMA Global has generated nearly 80 pieces of clinical research this year, much of which has the potential to help patients from Manhattan to Madrid and everywhere in between, today." Dr. Seli added, "This year's body of research presented just at ASRM covers a wide-range of topics facing our field including COVID-19, ovarian rejuvenation, genetic embryo testing, non-invasive embryonic testing to male fertility, and a survey study of the largest series of gay and bisexual men pursuing parenthood."

"It's like working at Apple. You have access to cutting edge technology to investigate the key issues and bring the most innovative solutions to patients," offered Dr. Nola Herlihy, second-year REI fellow, RMA New Jersey Jefferson University Fellowship Program. "I'm pleased that my colleagues Dr. Julia Kim, Dr. Brett Hanson, Dr. Amber Klimczak, and I were able to contribute to the RMA 2020 ASRM research effort so deeply."

The research presented by RMA at the 2020 ASRM includes:

Visit http://www.rmanetwork.com for a full list of accepted abstracts.

About Reproductive Medicine Associates (RMA)RMA is the U.S.-based network of fertility clinics that are part of IVIRMA Global. Founded in 2017 when the Valencian Infertility Institute (IVI) merged with RMA, IVIRMA Global comprises the largest group dedicated to assisted reproduction in the world.

IVIRMA Global currently has more than 70 centers in 11 countries with clinics in the United States, Spain, Portugal, Italy, United Kingdom, Panama, Argentina, Chile, and Brazil. Self-funded research, a fundamental pillar of the organization, supports the group's high success rates around the world.

To learn more about RMA, visit http://www.rmanetwork.com.

Christina Halper GoriniVictoryPublic Relations[emailprotected]

SOURCE Reproductive Medicine Associates

Home

Follow this link:

New Research from Reproductive Medicine Associates Demonstrates Commitment to Science, Success, and Support of Hopeful Infertility Patients Trying to...

Mount Sinai Doctors Elected to National Academy of Medicine for Contributions to Emergency Medicine and Translational Genetics – Newswise

Newswise (New York, NY October 19, 2020) Brendan G. Carr, MD, MA, MS, Chair of Emergency Medicine for the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, and Judy H. Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai and Director of The Charles Bronfman Institute for Personalized Medicine, have been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With their election, Mount Sinai has 25 faculty members in the NAM.

The recognitions of Dr. Carr and Dr. Cho are well deserved for their groundbreaking contributions to emergency medicine and translational genetics, says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai. Dr. Carrs research has focused not only on improving the emergency care system for time-sensitive conditions such as trauma, stroke, cardiac arrest, and sepsis, but also on creating a more distributed and innovative approach to increasing access to acute care. Likewise, Dr. Cho is committed to improving care through personalized medicine and the understanding of each patients unique genes. She has enhanced genetic research, clinical implementation, and data platforms to ensure Mount Sinai remains at the forefront of genetic discoveries and implementation.

Emergency Medicine A leading voice in emergency medicine, Dr. Carr played a central role in coordinating Mount Sinais response to the COVID-19 pandemic. He has dedicated his career as an emergency medicine physician and health policy researcher to seamlessly combining research, policy, and practice to advance acute care delivery. Before joining Mount Sinai in February 2020, Dr. Carr held faculty positions at the Sidney Kimmel Medical College at Thomas Jefferson University and the Perelman School of Medicine at the University of Pennsylvania.

Outside academia, Dr. Carr has worked within the U.S. Department of Health and Human Services during both the current and previous administrations to improve trauma and emergency care services at the national level. His roles have included Senior Advisor and Director of the Emergency Care Coordination Center within the Office of the Assistant Secretary for Preparedness and Response, focusing on integrating the emergency care system into the broader health care delivery system. He previously supported the Indian Health Services initiatives to improve emergency care delivery, and worked with the Department of Veterans Affairs and the Department of Defense to integrate military and civilian health care response during disasters and public health emergencies. Dr. Carr has advised and supported major not-for-profit foundations, the World Health Organization, and the National Academy of Medicine.

He conducts health services research that connects disciplines including epidemiology, health care policy, business, economics, and health care delivery system science. His work has been continuously funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. He has published and lectured widely on systems of care for trauma, stroke, cardiac arrest, and sepsis.

Ive spent my career focused on improving access to high-quality emergency care and am extremely humbled to be recognized by my peers with this honor. The recent COVID-19 surge reminded us of the importance of building robust systems that meet the needs of the communities that we serve. Im incredibly grateful for the opportunities Ive been given and the mentors that have helped to guide my career, says Dr. Carr. I am particularly grateful to be honored alongside my Mount Sinai colleague.

Translational Genetics Dr. Cho is an internationally recognized expert on the genetics and genomics of inflammatory bowel disease. As Dean of Translational Genetics, she leads strategic planning and integration of translational genetics research and care across school departments and institutes, with a focus on the rapid application of genetic and genomic discoveries to improve patient care. She also holds the Ward-Coleman Chair in Translational Genetics as well as professorships in Genetics and Genomic Sciences, and Medicine.

In 2013, Dr. Cho joined the Icahn School of Medicine faculty following appointments at the Yale University School of Medicine and the University of Chicago Pritzker School of Medicine. For the past five years, she has been Director of The Charles Bronfman Institute for Personalized Medicine and overseen the BioMe Biobank program, a pioneer in the movement toward diagnosis and classification of disease according to the patients molecular profile.

Science generally, and genetics especially, is a team sport; this recognition reflects many, many close collaborations over the years, says Dr. Cho. It is a privilege to try to advance science to help patients, and genetic discovery provides a particularly powerful means of prioritizing novel therapeutic targets.

Dr. Cho also leads an independent research program that is generously funded by the National Institutes of Health (NIH) and other extramural sources, and chairs the External Advisory Committee of the Wellcome Trust Centers for Human Genetics and Cellular Genetics. She has been Principal Investigator of the Data Coordinating Center for the Inflammatory Bowel Disease Genetics Consortium of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) since 2002 and chaired its Steering Committee for 16 years. Previously, she served on the American Society for Clinical Investigation Council and the NIDDK External Advisory Council, and chaired the Genetics of Health and Disease Study Section at the NIH. In 2014, Dr. Cho received the Crohns and Colitis Foundations Lifetime Achievement Award in Basic Science.

New members are elected to the NAM by current, active members through a selective process that recognizes leaders making major contributions to the advancement of the medical sciences, health care, and public health. Established in 1970 by the National Academy of Sciences, NAM is a national resource that provides independent, objective analysis and advice on health issues.

The elections of Dr. Carr and Dr. Cho bring Mount Sinais total membership in the prestigious group to 25 current and emeritus faculty members: Joseph D. Buxbaum, PhD Neil S. Calman, MD, MMS Dennis S. Charney, MD Kenneth L. Davis, MD Robert J. Desnick, MD, PhD Angela Diaz, MD, MPH Valentin Fuster, MD, PhD Bruce Gelb, MD Alison M. Goate, DPhil Kurt Hirschhorn, MD Yasmin L. Hurd, PhD Philip J. Landrigan, MD, MSc Helen S. Mayberg, MD Diane E. Meier, MD Eric J. Nestler, MD, PhD Maria Iandolo New, MD Peter Palese, PhD Ramon E. Parsons, MD, PhD Lynne D. Richardson, MD Hugh A. Sampson, MD Albert Siu, MD, MSPH Barbara G. Vickrey, MD, MPH Rachel Yehuda, PhD.

About the Mount Sinai Health System

The Mount Sinai Health System is New York Citys largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's Honor Roll of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in the country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Go here to read the rest:

Mount Sinai Doctors Elected to National Academy of Medicine for Contributions to Emergency Medicine and Translational Genetics - Newswise

ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China – BioSpace

Oct. 19, 2020 12:45 UTC

Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicines Oncology Portfolio with Innovative ADC

Combines ImmunoGens Lead Clinical Program with Huadongs Regional Oncology Expertise

ImmunoGen to Receive $40 MillionUpfront Payment and is Eligible to Receive Up to $265 Million in Potential Development, Regulatory, and Commercial Milestone Payments

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc.. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd., today announced that the companies have entered into an exclusive collaboration to develop and commercialize mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan (Greater China). ImmunoGen will retain all rights to mirvetuximab in the rest of the world.

This collaboration provides ImmunoGen with access to the second largest pharmaceutical market in the world via Huadong Medicines development, regulatory, and commercial capabilities, while supporting Huadong Medicines growth strategy to build a deep portfolio of oncology, endocrinology, and autoimmunology candidates. Mirvetuximab adds a compelling late-stage oncology asset to Huadong Medicines portfolio.

"With extensive regional experience, the right development and regulatory capabilities, and access to a deep local network of hospitals and clinics across Greater China, Huadong Medicine is an ideal partner for us, said Mark Enyedy, ImmunoGens President and Chief Executive Officer. This collaboration reflects mirvetuximabs potential to deliver meaningful value to ovarian cancer patients as well as our ability to translate our work in ADCs into long-term relationships that create sustainable value for ImmunoGen and our partners. We look forward to working closely with Huadong Medicine to develop and commercialize mirvetuximab in Greater China as we advance the mirvetuximab program and prepare for the first potential commercial launch in the United States in 2022.

"ImmunoGen is a leader in the development of ADCs for the treatment of cancer and this partnership provides us with a late-stage asset that will enable us to further expand our pipeline of innovative oncology programs, said Liang Lu, Chairman of Huadong Medicine. The compelling clinical data generated to date highlights mirvetuximabs potential to be a promising therapy for an extremely difficult to treat disease and we look forward to beginning its development as we seek to meet the growing needs of ovarian cancer patients in Greater China."

Under the terms of the agreement, ImmunoGen will receive an upfront payment of $40 million and is eligible to receive additional milestone payments of up to $265 million as certain development, regulatory, and commercial objectives are achieved. ImmunoGen is also eligible to receive low double digit to high teen royalties as a percentage of mirvetuximab commercial sales by Huadong Medicine in Greater China.

Huadong Medicine will be responsible for the development as well as potential regulatory submissions and commercialization of mirvetuximab in Greater China pursuant to input from a joint steering committee comprised of individuals from both companies. Huadong Medicine will also have the opportunity to participate in global clinical studies of mirvetuximab conducted by ImmunoGen. ImmunoGen will continue to be responsible for the development and commercialization of mirvetuximab in the United States and other geographies.

ABOUT MIRVETUXIMAB SORAVTANSINE

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FR)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent to kill the targeted cancer cells.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to target a better now.

Learn more about who we are, what we do, and how we do it at http://www.immunogen.com.

ABOUT HUADONG MEDICINE

Huadong Medicine Co., Ltd. (SZ.000963) is a leading Chinese pharmaceutical company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales and marketing capabilities. Huadong Medicines product portfolio and pipeline are specialized in oncology, immunology, nephrology and diabetes. The Companys annual revenue in 2019 exceeded 5 billion USD. Huadong Medicine has 12,000 employees among which 1,000 are dedicated to R&D. Huadong Medicine possesses one of the most extensive commercial coverage and marketing capabilities in China. Patient Centered, Science Driven is Huadongs value. For additional information, please visit http://www.eastchinapharm.com/en.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGens expectations related to: the occurrence, timing, and outcome of potential pre-clinical, clinical, and regulatory events related to ImmunoGens product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGens actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the successful execution of the collaboration with Huadong and their development and commercialization efforts; the timing and outcome of ImmunoGens pre-clinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of pre-clinical studies, clinical trials, and regulatory processes; ImmunoGens ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting impact on ImmunoGens industry and business; and other factors more fully described in ImmunoGens Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005214/en/

See the rest here:

ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China - BioSpace


12345...102030...